Literature DB >> 23415136

Obesity does not adversely affect outcomes after laparoscopic splenectomy.

Helen M Heneghan1, Shohrat Annaberdyev, Vikram Attaluri, Tracy Pitt, Matthew Kroh, Sri Chalikonda, Stacy A Brethauer, Steven Rosenblatt.   

Abstract

BACKGROUND: Obesity is still considered a relative contraindication to laparoscopic splenectomy (LS).
METHODS: All patients undergoing LS at our institution were classified as obese or nonobese (group A, body mass index [BMI] >30; group B, BMI <30). Primary end points included conversion rate, operative complications, length of stay, operative time, and estimated blood loss (EBL).
RESULTS: Three hundred seventy patients who underwent LS were included. Baseline characteristics were similar in groups A (n = 127; mean BMI, 36.2 ± 6.9 kg/m²) and B (n = 243; mean BMI, 24.6 ± 2.9 kg/m²). Conversion rates and overall morbidity were similar in both groups (9% vs 11% for conversion to open procedures, P = .621; 16% vs 16% for morbidity rates, P = .940). Length of hospital stay and EBL were also comparable (P = .643 and P = .544, respectively). Mean operative time was significantly increased in the obese group on multivariate analysis (170 vs 151 minutes, P = .021).
CONCLUSIONS: Obesity does not adversely affect outcomes after LS. The laparoscopic approach is the optimal technique for splenectomy regardless of the patient's weight.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23415136     DOI: 10.1016/j.amjsurg.2012.07.041

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  2 in total

1.  The Effect of Age upon the Interrelationship of BMI and Inpatient Health Outcomes.

Authors:  C Woolley; C Thompson; P Hakendorf; C Horwood
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

2.  Laparoscopic splenectomy: perioperative management, surgical technique, and results.

Authors:  P Marco Fisichella; Yee M Wong; Sam G Pappas; Gerard J Abood
Journal:  J Gastrointest Surg       Date:  2013-10-10       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.